Stay updated on DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Sign up to get notified when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.

Latest updates to the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and Revision: v3.4.1.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding lapse notice was added, noting possible delays and directing readers to cc.nih.gov and opm.gov for status updates. The page revision changed from v3.4.0 to v3.4.1 and added related topics such as Type 2 diabetes and MedlinePlus Genetics.SummaryDifference0.4%

- Check28 days agoChange DetectedAdded a 'Show glossary' option and updated metadata fields to include 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', plus a revision note 'Revision: v3.4.0'. The previous labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed or updated accordingly.SummaryDifference0.1%

- Check35 days agoChange DetectedThe page no longer lists the condition 'Type 2 diabetes' and the related topic 'MedlinePlus Genetics'. This reduces the explicit tagging of the study's focus and related resources on the page.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no changes to core study content, eligibility criteria, outcomes, or locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedThe Locations section was reorganized to add a top-level Locations header and individual province/municipality subsections (Anhui, Beijing Municipality, Chongqing Municipality, etc.), replacing the previous per-location headers.SummaryDifference2%

Stay in the know with updates to DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DONATE Study: Dapagliflozin Safety in T2DM Clinical Trial page.